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T he number of patients with cardiac implantable electronic devices (CIED) in Japan is rapidly 
increasing (with 75,112 implantations performed in 
2019) because of broad indications for pacing devices 
and increased life expectancy <Japan Arrhythmia 
Device Industry Association: https://www.jadia.or.jp/
medical/crt-p.html,  https://www.jadia.or.jp/medical/
crt-d.html (accessed May 10, 2021.)>.  Previously,  CIED 
were considered an absolute contraindication to mag-
netic resonance imaging (MRI) because of the poten-
tially life-threatening interactions between the devices 
and magnetic fields or high-frequency pulses.  With the 
development of MRI-conditional CIED,  MRI scans in 
patients with CIED are now routine in many hospitals 
[1].  However,  most institutional safety protocols 
include several limitations regarding patient selection 
for MRI,  leaving MRI unavailable to many acute stroke 
patients.
Although diagnostic and therapeutic strategies for 
acute stroke patients in Japan depend largely on MRI 
[2],  patients with CIED must still rely on computed 
tomography (CT).  Patients with CIED are thus at a 
potential disadvantage due to the resultant delay in the 
diagnosis of acute ischemic stroke.  However,  these 
issues have not been as well recognized in the field of 
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Although diagnostic and therapeutic strategies for acute stroke patients in Japan depend largely on magnetic 
resonance imaging (MRI),  patients with cardiac implantable electronic devices (CIED) must still rely on com-
puted tomography (CT).  We retrospectively analyzed clinical and neuroimaging data of ischemic stroke 
patients with CIED treated at our hospital.  Forty-five patients were enrolled in the study.  Patients were divided 
into two groups according to whether corresponding lesions were detected (group A,  n = 21) or not detected 
(group B,  n = 24) by the first brain CT.  We also evaluated in detail the clinical courses of patients who arrived at 
hospital within therapeutic time windows for recanalization therapy.  Negative fresh infarct in the first CT was 
associated,  though not significantly,  with early onset-to-arrival time and subcortical white matter infarction.  
Five patients did not undergo recanalization therapy because their families did not agree to the procedure.  The 
reasons for their lack of consent included inadequate information about the safety and efficacy of recanalization 
therapy because MRI could not be performed.  Our study confirmed delayed detection of the corresponding 
lesion and undertreatment for acute stroke in patients with CIED.
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cardiology,  as they have in neurology.
In the present study,  to investigate how CIED influ-
ence the diagnosis,  recanalization therapy,  and prog-
nosis of acute ischemic stroke in patients with CIED,  we 
retrospectively compared the cases of ischemic stroke 
patients with CIED in whom the corresponding lesions 
were or were not detected by the first brain CT.
Materials and Methods
This retrospective study was approved by the 
Institutional Review Board of Saitama Medical 
University International Medical Center (approval 
number: 15-053).  Patients were not required to give 
informed consent to participate in the study because the 
analysis used anonymous clinical data that were 
obtained after each patient had provided written con-
sent to treatment.  Also,  we applied an opt-out method 
to obtain consent for this study through an announce-
ment on our hospital’s website.  The announcement was 
approved by the Institutional Review Board.
We retrospectively analyzed the clinical and neuro-
imaging data of acute ischemic stroke patients with 
CIED treated at our hospital between April 2007 (when 
the hospital opened) and March 2016.  Acute ischemic 
stroke was defined as hospital arrival within 7 days of 
symptom onset.  The data were obtained from electronic 
medical charts and summaries.  We evaluated the patients’ 
characteristics (age,  sex),  the causative arrhythmia,  
type of CIED,  underlying stroke risk factors (atrial 
fibrillation,  coronary artery disease,  hypertension,  
diabetes mellitus,  dyslipidemia,  current smoking,  
prior stroke),  echocardiographic findings,  laboratory 
data (D-dimer,  brain natriuretic peptide) on admission,  
and use of antithrombotic (antiplatelet and/or antico-
agulant) agents before the index stroke.
We also evaluated the onset situation (awake or 
asleep),  mode of arrival at the hospital,  onset-to- 
arrival time,  initial symptoms,  National Institutes of 
Health Stroke Scale (NIHSS) score,  stroke subtype,  
brain CT findings,  functional outcome using the mod-
ified Rankin scale score [3] at discharge,  and the dura-
tion of hospital stay.  Stroke subtypes were defined 
according to the Trial of ORG 10172 in the Acute Stroke 
Treatment Subtype Classification [4].
All CT imaging was performed on a 64-row multi- 
detector CT scanner (General Electric LightSpeed VCT 
system; GE Healthcare,  Milwaukee,  WI,  USA).  A 
standard axial CT of the whole brain was performed 
with a sequential technique for a 5-mm slice thickness.  
CT was used to identify the infarct in all patients,  and 
infarct size was defined as follows: small,  longest 
diameter ≤ 15 mm; large,  infarct larger than one-third 
of the territory of the middle cerebral artery,  anterior 
cerebral artery,  posterior cerebral artery,  or cerebellar 
hemisphere; all other sizes were classified as medium 
[5].  CT cerebral angiography was used in some 
patients.  White matter lesions were classified on a scale 
of 0-3 according to their location and size by grade [6].  
Patients were divided into 2 groups: those with fresh 
infarcts detected by the initial CT (group A) and those 
in whom fresh infarcts were not detected by the initial 
CT (group B).  The therapeutic strategies did not differ 
between the groups.  The protocol of recanalization 
therapy for hyperacute ischemic stroke patients with 
CIED at our institute was as follows: (i) noncontrast 
CT-based exclusion of symptomatic intracranial hem-
orrhage,  (ii) CT angiography and/or perfusion CT was 
also performed if it would not unduly delay recanaliza-
tion therapy.
In Japan,  a recombinant tissue-type plasminogen 
activator (rt-PA) was approved in October 2005 for use 
within 3 h of stroke onset.  In August 2012,  the thera-
peutic time window was extended to within 4.5 h of 
symptom onset.  To investigate how CIED influence 
acute recanalization therapy,  we confirmed the clinical 
courses of patients who underwent recanalization ther-
apy.  For those who did not receive this therapy,  we 
assessed the reason why.  Our hypothesis was that the 
inability to diagnose a stroke using MRI could decrease 
the frequency of recanalization therapy.
Statistical analysis was performed using PASW sta-
tistical software (version 20; IBM Corp.,  Armonk,  NY,  
USA).  Wilcoxon’s rank-sum test and Pearson’s chi-
square test were used to compare the characteristics 
between the groups.
Results
Forty-nine patients with CIED were admitted 
because of ischemic stroke,  but we excluded 4 patients 
because they were diagnosed as having transient isch-
emic attacks.  Therefore,  the final study sample size was 
45 patients.  The patients included in this study repre-
sent 1.5% of the total number of patients (n = 2,997) 
with ischemic stroke admitted to our institution.  The 
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study flowchart is shown in Fig. 1.  Corresponding 
lesions were detected in 21 patients (47%) on the initial 
CT (group A); 24 patients (53%) did not show corre-
sponding lesions on the initial CT (group B).  In group 
B,  2 patients had a hyperdense middle cerebral artery 
sign and 2 others had a middle cerebral artery dot sign.  
One patient underwent enhanced CT on admission,  
and corresponding vessel occlusion was confirmed.  All 
patients underwent a second CT; fresh lesions were 
newly confirmed in 15 patients at a mean of 1.8 days 
after the first CT,  and hypodense area expansion was 
confirmed in 7 patients at a mean of 4.1 days after the 
first CT.  In group B,  2 patients experienced a 1-day 
delay in treatment because corresponding lesions were 
not detected on the first CT at the previous institutions.
The baseline characteristics of the patients in each 
group are listed in Table 1.  There were no significant 
differences between the groups except for coronary 
artery disease.  Stroke characteristics in the 2 groups are 
listed in Table 2.  All patients arrived at hospital within 
72 h of stroke onset.  Onset-to-arrival time was longer 
in group A than in group B (median: 2.25 h versus 1 h,  
respectively; p = 0.266).  Two or more infarct locations 
were the most frequent in both groups,  and almost all 
lesions were cerebral cortico-subcortical.  Subcortical 
white matter was a more frequent location in group B 
than in group A (34% versus 5%,  respectively; p=0.101),  
but the difference was not statistically significant.  
Although the ratio of good functional outcome at 
discharge (modified Rankin scale score: 0 or 1) was 
higher in group B (29%) than in group A (10%),  the 
difference was not significant (p = 0.143).
Onset-to-arrival time was within 4.5 h in 31 patients 
(69%),  and in 2 of the 31 patients it was within 3-4.5 h 
(1 patient in each group).  The characteristics of 4 patients 
(3 in group A and 1 in group B) treated with acute reca-
nalization therapy are listed in Table 3.  Two patients 
were treated with recanalization therapy based on CT 
only,  without contrast enhancement.  Intravenous rt-PA 
was effective in 1 patient,  but cardioembolic stroke 
recurred during that patient’s hospital stay.  Symp-
tomatic hemorrhagic transformation was seen in 1 
patient.  The effectiveness of recanalization therapy var-
ied depending on the patient.
Twenty-seven patients did not undergo recanaliza-
tion therapy despite their arrival within the therapeutic 
time windows.  The most common reasons for not 
receiving rt-PA treatment were mild or rapid improve-
ment in symptoms (n = 12),  CT findings of major 
infarct signs (n = 6),  lack of consent by the family 
(n = 5),  active bleeding (n = 2),  and prothrombin time/
international normalized ratio > 1.7 (n = 2).  Factors 
influencing the families’ decisions to disagree rt-PA 
treatment included inadequate information regarding 
the safety and efficacy of rt-PA because MRI could not 
be performed.  Without MRI,  the sizes of the infarct 
and the occluded vessel remain speculative,  thus hin-
dering a family’s ability to decide on this possibly harm-
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Acute ischemic stroke patients with  a CIED (n=49)
Exclusion
owing to TIA (n=4)
Patients with acute cerebral infarction (n=45)
Was a fresh infarct detected on the first CT?
Group A (n=21)
Detected on the first CT
as fresh infarcts (n=21)
Positive vessel image on the first CT (n=5)
hyperdense MCA sign (n=2), dot sign (n=2)
vessel occlusion on enhanced CT (n=1)
Group B (n=24)
Detected on the second CT
as fresh infarcts 1.8 days later (n=15)
as expansion of the hypodense area 4.1 days later (n=7)
Not detected on follow-up CT (n=2)
NoYes
Fig. 1　 Patient flowchart.
CIED,  cardiac implantable electronic device; TIA,  transient ischemic attack; CT,  computed tomography; MCA,  middle cerebral artery.
ful intervention.  The characteristics of the 5 patients (1 
in group A and 4 in group B) who did not undergo 
recanalization therapy due to family disagreement are 
listed in Table 4.  All 5 of these patients had poor func-
tional outcomes at discharge (modified Rankin scale 
score ≥ 5).  Although 5 patients in this study had MRI-
conditional CIED,  brain MRI was not performed 
during the acute stroke phase in these patients.
Discussion
In less than half of the patients with CIED (47%),  
corresponding lesions were detected by the first CT 
without contrast enhancement.  Accordingly,  a delay in 
stroke treatment occurred in 2 patients (group B),  but 
the functional outcomes did not differ between the 
patients in whom corresponding lesions were detected 
and those in whom they were not detected by the first 
CT.  Previous studies showed that the sensitivity of CT 
in detecting cortical infarcts is relatively high because 
CT visualizes both density change and swelling,  
whereas the sensitivity of CT in identifying ischemic 
lesions is poor in patients with mild stroke (NIHSS < 4) 
or with small infarcts (< 1 mL) [8-10].  Although our 
study population included many patients who had cor-
tical infarcts and moderate strokes (median NIHSS: 8 
in group A and 9 in group B),  the sensitivity of the first 
CT in identifying corresponding lesions did not reach 
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Table 1　 Background characteristics of the patients with a cardiac implantable electronic device
Group A: Detected on
initial CT
N=21




Age (years) 78±7 77±13 0.945
Women (%) 8 (38) 11 (46) 0.764
Causative arrhythmias 1.000
　SSS (%) 11 (52) 10 (42)
　AVB (%) 5 (24) 11 (46)
　Others (%) 5 (24) 3 (12)
Type of CIED 0.608
　pacemaker (%) 19 (90) 20 (84)
　ICD (%) 2 (10) 2 (8)
　CRT pacemaker (%) 0 (0) 1 (4)
　CRT defibrillator (%) 0 (0) 1 (4)
Time since device implantation (years) 6.7±8.7 6.7±6.5 0.436
Stroke risk factors
　Atrial fibrillation (%) 12 (57) 13 (54) 1.000
　Coronary artery disease (%) 1 (5) 9 (38) 0.010
　Hypertension (%) 10 (48) 15 (63) 0.377
　Diabetes mellitus (%) 3 (14) 4 (17) 1.000
　Dyslipidemia (%) 3 (14) 6 (25) 0.469
　Current smoking (%) 1 (5) 2 (8) 1.000
　Prior stroke (%) 3 (14) 5 (21) 0.705
Echocardiographic findings
　Left atrial dimensions (mm) 42.5±8.7 40.6±7.7 0.349
　Ejection fraction (%) 57±14 62±16 0.180
Laboratory data on admission
　D-dimer (µg/mL) 6.9±22.5 3.6±3.6 0.146
　Brain natriuretic peptide (pg/mL) 854±1,201 699±371 0.374
Antithrombotic treatment
　Anticoagulant only (%) 3 (14) 6 (25) 0.469
　Antiplatelet only (%) 8 (38) 9 (38) 1.000
　Combined therapy (%) 1 (5) 2 (8) 1.000
AVB,  atrioventricular block; CIED,  cardiac implantable electronic devices; CRT,  cardiac resynchronization therapy; CT,  computed 
tomography; ICD,  implantable cardioverter defibrillator; SSS,  sick sinus syndrome.  Date are given as mean ± standard deviation,  or 
number (%).
50%.  Although MRI with diffusion-weighted images is 
more accurate than CT for diagnosing acute ischemic 
stroke [9-10],  our present series of patients with CIED 
have not received the benefits of MRI yet.  Although the 
prevalence of coronary artery disease was significantly 
higher in group A than in group B,  the difference was 
probably attributable to the small sample size.
In our study,  only 4 patients (3 in group A and 1 in 
group B) underwent recanalization therapy.  It might be 
considered that patients in group B would be better 
candidates for recanalization therapy than those in 
group A,  but actually it’s not.  Although recanalization 
therapy is effective and safe for ischemic stroke patients 
within 3 h after onset even with a CT-based diagnosis 
[11],  undetection of corresponding lesions may have 
made physicians hesitate to choose recanalization ther-
apy and thus led families not to agree to the treatment.  
Although it was reported that stroke physicians could 
choose recanalization therapy with more certainty in 
MRI-based patient selection than in CT-based patient 
selection [12],  they need to choose CT-based recanali-
zation therapy without hesitation in patients with CIED.
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Table 2　 Stroke characteristics of the patients with a cardiac implantable electronic device
Group A: Detected on
initial CT
N=21




Onset situation,  n (%) 1.000
　awake 17 (81) 20 (83)
　asleep 4 (19) 4 (17)
Method of transport to hospital,  n (%) 0.351
　ambulance 15 (71) 21 (88)
　walk-in 5 (24) 2 (8)
　in-hospital onset 1 (5) 1 (4)
Onset-to-arrival time,  hours 2.25 (1-11.75) 1 (1-2.75) 0.266
Initial symptoms,  n (%)
　facial palsy 12 (57) 11 (46) 0.554
　hemiparesis 18 (86) 18 (75) 0.469
　speech impairment 15 (71) 15 (63) 0.752
NIHSS score on admission 8 (3-15) 9 (2-15) 0.882
Stroke subtype,  n (%) 0.829
　Cardioembolic 19 (90) 20 (83)
　Atherosclerotic 1 (5) 3 (13)
　Lacunar 1 (5) 1 (4)
Stroke location,  n (%) 0.101
　Two or more infarct locations 16 (75) 13 (54)
　Cerebral cortex 1 (5) 0 (0)
　Subcortical white matter 1 (5) 8 (34)
　Basal ganglia 1 (5) 0 (0)
　Brainstem 1 (5) 0 (0)
　Cerebellum 1 (5) 1 (4)
　Invisible 0 (0) 2 (8)
Stroke size,  n (%) 0.166
　Large 11 (52) 9 (38)
　Medium 9 (43) 9 (38)
　Small 1 (5) 6 (24)
White matter lesion,  grade 1 (0-2) 1 (0-2) 0.582
Outcomes
　mRS score at discharge 4 (3-5) 4.5 (1-5) 0.617
　mRS score 0 and 1 at discharge,  n (%) 2 (10) 7 (29) 0.143
Duration of hospital stay,  days 35 (27-46) 29 (12.8-53) 0.495
CT,  computed tomography; NIHSS,  National Institutes of Health Stroke Scale; mRS,  modified Rankin Scale. Date are given as number 
(%),  or median (interquartile range).
In a previous report,  MRI-required events after 
CIED implantation cumulatively increased at the rate of 
5.3% per year [13].  Among such events,  intracranial 
disease was the most frequent,  accounting for 43% of 
the total events [13].  MRI examinations in patients with 
CIED require special attention as well as several steps 
from the referring stroke department along with the 
radiology and cardiology departments.  It would be bet-
ter for each hospital to establish a protocol to promptly 
perform MRI for acute stroke patients with CIED,  
though only the minimum imaging examination (e.g.,  
CT without contrast enhancement) is required by 
Japanese guidelines for intravenous rt-PA [2].
This study had several limitations.  First,  this was a 
single-center,  retrospective study.  Second,  the number 
of patients was small,  and they were followed up only 
during their hospital stay.  In some patients,  functional 
outcomes may recover after discharge.  Third,  we did 
not compare stroke characteristics between patients 
with and those without CIED.
Our study confirmed the delayed detection of the 
corresponding lesion in patients with CIED.  Although 
intravenous rt-PA is an approved treatment for acute 
ischemic stroke within 4.5 h of symptom onset [2],  
patients with CIED are still left undertreated because of 
the inability to reach a diagnosis using MRI.  Although 
better functional outcomes were expected in group B 
than in group A because of the earlier onset-to-arrival 
time in group B patients,  functional outcomes did not 
differ between the 2 groups.  We speculate that the 
inability to diagnose with MRI caused a delay or hesita-
tion in acute stroke treatment,  leading to poorer func-
tional outcomes in some patients.  Recently,  MRI-
conditional CIED has been clinically introduced,  and 
this may be desired to create an environment in which 
patients with CIED receive the benefits of MRI in acute 
stroke practice.
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Table 4　 Stroke characteristics of the patients untreated with recanalization therapy for family disagreement
Patient,  Group 1,  A 2,  B 3,  B 4,  B 5,  B
Age,  Sex 81,  M 76,  F 81,  M 81,  F 79,  F
Onset-to-arrival time,  hours 1 1 2 1 3.5
NIHSS on admission 15 27 21 11 21
Stroke subtype Cardioembolic Atherothrombotic Cardioembolic Atherothrombotic Cardioembolic
Atrial fibrillation － － + － －
mRS score at discharge 5 5 6 5 5
M,  male; F,  female; NIHSS,  National Institutes of Health Stroke Scale score; mRS,  modified Rankin Scale.
Table 3　 Stroke characteristics of the patients treated with recanalization therapy
Patient,  Group 1,  A 2,  A 3,  A 4,  B
Age,  Sex 85,  F 70,  M 76,  M 92,  M
Onset-to-arrival time,  hours 0.75 1 1 1
NIHSS on admission 20 21 13 9
Stroke subtype Cardioembolic Cardioembolic Cardioembolic Cardioembolic
Atrial fibrillation + － + －
ASPECT 9 9 8 10
Occluded artery ICA MCA ICA MCA
Diagnostic imaging CT-Angiography, CT-Perfusion CT-Perfusion
CT without contrast 
enhancement
CT without contrast 
enhancement
Recanalization therapy rt-PA rt-PA rt-PA,  EVT rt-PA
Symptomatic hemorrhagic transformation － － + －
mRS score at discharge 5# 2 4 4
＃Intravenous rt-PA was effective in patient 1,  but cardioembolic stroke recurred during hospital stay.
ASPECT,  Alberta Stroke Program Early CT Score [7]; CT,  computed tomography; EVT,  endovascular therapy; F,  female; ICA,  internal 
carotid artery; NIHSS,  National Institutes of Health Stroke Scale score; M,  male; MCA,  middle cerebral artery; mRS,  modified Rankin 
Scale; rt-PA,  recombinant tissue-type plasminogen activator.
References
 1.  Maass AH,  Hemels MEW and Allaart CP: Magnetic resonance 
imaging in patients with cardiac implantable electronic devices.  
Neth Heart J (2018) 26: 584-590.
 2.  Toyoda K,  Koga M,  Iguchi Y,  Itabashi R,  Inoue M,  Okada Y,  
Ogasawara K,  Tsujino A,  Hasegawa Y,  Hatano T,  Yamagami H,  
Iwama T,  Shiokawa Y,  Terayama Y and Minematsu K: Guidelines 
for Intravenous Thrombolysis (Recombinant Tissue-type Plasminogen 
Activator),  the Third Edition,  March 2019: A Guideline From the 
Japan Stroke Society.  Neurol Med Chir (Tokyo) (2019) 59: 449-
491.
 3.  Sulter G,  Steen C and De Keyser J: Use of the Barthel index and 
modified Rankin scale in acute stroke trials.  Stroke (1999) 30:  
1538-1541.
 4.  Adams HP Jr,  Bendixen BH,  Kappelle LJ,  Biller J,  Love BB,  
Gordon DL and Marsh EE 3rd: Classification of subtype of acute 
ischemic stroke.  Definitions for use in a multicenter clinical trial.  
TOAST.  Trial of Org 10172 in Acute Stroke Treatment.  Stroke 
(1993) 24: 35-41.
 5.  Toyoda K,  Arihiro S,  Todo K,  Yamagami H,  Kimura K,  Furui E,  
Terasaki T,  Shiokawa Y,  Kamiyama K,  Takizawa S,  Okuda S,  
Okada Y,  Kameda T,  Nagakane Y,  Hasegawa Y,  Mochizuki H,  
Ito Y,  Nakashima T,  Takamatsu K,  Nishiyama K,  Kario K,  Sato S,  
Koga M and SAMURAI Study Investigators: Trends in oral antico-
agulant choice for acute stroke patients with nonvalvular atrial 
fibrillation in Japan: the SAMURAI-NVAF study.  Int J Stroke (2015) 
10: 836-842.
 6.  Wahlund LO,  Barkhof F,  Fazekas F,  Bronge L,  Augustin M,  
Sjögren M,  Wallin A,  Ader H,  Leys D,  Pantoni L,  Pasquier F,  
Erkinjuntti T,  Scheltens P and European Task Force on Age-
Related White Matter Changes: A new rating scale for age-related 
white matter changes applicable to MRI and CT.  Stroke (2001) 32:  
1318-1322.
 7.  Barber PA,  Demchuk AM,  Zhang J and Buchan AM: Validity and 
reliability of a quantitative computed tomography score in predict-
ing outcome of hyperacute stroke before thrombolytic therapy.  
ASPECTS Study Group.  Alberta Stroke Programme Early CT Score.  
Lancet (2000) 355: 1670-1674.
 8.  Barber PA,  Hill MD,  Eliasziw M,  Demchuk AM,  Pexman JH,  
Hudon ME,  Tomanek A,  Frayne R,  Buchan AM and ASPECTS 
Study Group: Imaging of the brain in acute ischaemic stroke:  
comparison of computed tomography and magnetic resonance dif-
fusion-weighted imaging.  J Neurol Neurosurg Psychiatry (2005) 
76: 1528-1533.
 9.  Chalela JA,  Kidwell CS,  Nentwich LM,  Luby M,  Butman JA,  
Demchuk AM,  Hill MD,  Patronas N,  Latour L and Warach S:  
Magnetic resonance imaging and computed tomography in emer-
gency assessment of patients with suspected acute stroke: a pro-
spective comparison.  Lancet (2007) 369: 293-298.
10.  Moreau F,  Asdaghi N,  Modi J,  Goyal M and Coutts SB: Magnetic 
resonance imaging versus computed tomography in transient isch-
emic attack and minor stroke: the more you see the more you 
know.  Cerebrovasc Dis Extra (2013) 3: 130-136.
11.  Köhrmann M ,  Jüttler E,  Fiebach JB,  Huttner HB,  Siebert S,  
Schwark C,  Ringleb PA,  Schellinger PD and Hacke W: MRI ver-
sus CT-based thrombolysis treatment within and beyond the 3 h 
time window after stroke onset: A cohort study.  Lancet (2006) 5:  
661-667.
12.  Hansen CK,  Christensen A,  Rodgers H,  Havsteen I,  Kruuse C 
and Christensen H: Does the primary imaging modality-computed 
tomography or magnetic resonance imaging-influence stroke physi-
ciansʼ certainty on whether or not to give thrombolysis to random-
ized acute stroke patients? J Stroke Cerebrovasc Dis (2018) 27:  
926-935.
13.  Taruya A,  Tanaka A,  Nishiguchi T,  Iwaguro T,  Ueno S,  Okumoto Y,  
Kubo T,  Akagi H and Akasaka T: Necessity of magnetic reso-
nance imaging examinations after permanent pacemaker implanta-
tion.  Int J Cardiol (2015) 184: 497-498.
December 2021 Acute Stroke Practice in Patients with CIED 697
